


DDO-2213

Cat. No.:	HY-153331
CAS No.:	2378768-36-4
Molecular Formula:	C ₂₄ H ₂₇ ClFN ₇ O
Molecular Weight:	483.97
Target:	WDR5
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC₅₀ of 29 nM and a K_d value of 72.9 nM for the WDR5 protein. DDO-2213 selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research^[1].

REFERENCES

[1]. Chen W, et al. Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia. *J Med Chem.* 2021 Jun 24;64(12):8221-8245.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA